Charles Levea

Charles LeVea

MD, PhD

Specializing In:

Colon cancer Rectal cancer Gastrointestinal surgical pathologist Oncologic Surgical Pathology Fellowship and UB Resident education Graduate and medical school education Departmental leadership

Special Interests:

Signaling pathways involved in upper and lower gastrointestinal cancers Gastrointestinal Pathology Disease Site Research Group Digital pathology Machine learning and artificial intelligence applications to pathology

About Me

Biography:

Charles M. LeVea MD, PhD, was appointed Chair of the Department of Pathology & Laboratory Medicine in July 2017. Before that appointment, he was Vice Chair and Director of Surgical Pathology at Roswell Park. Dr. LeVea has a doctorate in experimental pathology from the University of Pennsylvania. His medical degree is from Stony Brook University, and he completed residency and fellowship training at the University of Rochester, Strong Memorial Hospital /Wilmot Cancer Center.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Chair, Department of Pathology and Laboratory Medicine

Background

Education and Training:

  • 1996 - MD - State University of New York at Stony Brook, Brookhaven, NY
  • 1992 - PhD - Experimental Pathology, University of Pennsylvania, Philadelphia, PA
  • MS - University of Rochester, Rochester, NY

Residency:

  • 1996-2000 - Anatomic & Clinical Pathology, University of Rochester, Rochester, NY

Fellowship:

  • 2000 - 2003 - Wilmot Fellowship, EGFR Signaling & Surgical Pathology, University of Rochester, Rochester, NY

Board Certification:

  • 2001 - Anatomic Pathology, American Board of Pathology
  • 2001 - Clinical Pathology, American Board of Pathology

Professional Memberships:

  • Association of Pathology Chairs
  • College of American Pathologists
  • United States & Canadian Academy of Pathology
  • American Society for Clinical Pathology
  • Western New York Society of Surgical Pathologists

Honors & Awards

  • 2007-2012 - University at Buffalo Outstanding ACGME Accreditation Award
  • 2010 - Dr. Edith E. Sproul Teaching Award for outstanding commitment and dedication to fellow education
  • 2013-2014 - University at Buffalo Outstanding ACGME Accreditation Award
  • Leadership Development for Physicians in Academic Health Centers, Harvard School of Public Health, Boston Massachusetts (Eoin W. Trevelyan, D.B.A.)
  • Executive Development RV Rhodes
  • Pathology Leadership Academy by Association of Pathology Chairs

Publications

  • Chung AY, Li Q, Blair SJ, De Jesus M, Dennis KL, LeVea C, Yao J, Sun Y, Conway TF, Virtuoso LP, Battaglia NG, Furtado S, Mathiowitz E, Mantis NJ, Khazaie K, Egilmez NK. Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. Cancer Res (2014) 74(19):5377-5385. PMID: 25228656
  • S T Glenn, C A Jones, S Sexton, C M LeVea, S M Caraker, G Hajduczok and K W Gross. Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma. Oncogene (2014) Dec 11; 33(50):5706-5715. doi: 10.1038/onc.2013.514. PMID: 24292676
  • H Zhang, B L Hylander, C LeVea, E A Repasky, R M Straubinger, A A Adjei and W W Ma. Enhanced FGFR signaling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. British Journal of Cancer (2014) 110(2):320–329 PMID: 24327018
  • Eisar Al-Sukhni, Charles LeVea, John Kane, Joseph Skitzki, and Valerie Francescutti. Key Gaps in Pathologic Reporting for Appendiceal Mucinous Neoplasms: Time for Universal Synoptic Reporting? Annals of Diagnostic Pathology (2016) http://dx.doi.org/10.1016/j.anndiagpath.2016.06.004 PMID: 27649955
  • Yukihiro Nakanishi, MD, PhD; Charles LeVea, MD; Shiva Dibaj, MS; Fadi Habib, MD; Richard Cheney, MD; Kazunori Kanehira, MD. Reappraisal of Serosal Invasion in Patients With T3 Colorectal Cancer by Elastic Stain: Clinicopathologic Study of 139 Surgical Cases With Special Reference to Peritoneal Elastic Lamina Invasion. Arch Pathol Lab Med. (2016) 140:81–85; doi: 10.5858/arpa.2014-0647-OA PMID: 26717059.
  • Alexiev BA, Levea CM. Nephrogenic adenoma of the urinary tract: a review. International journal of surgical pathology 2012; 202:123-131
  • Teng BP, Heffler MD, Lai EC, Zhao Y-L, LeVea CM, Golubovskaya VM, BullardDunn KM. Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis. Anti-cancer agents in medicinal chemistry 2011; 117:620-628
  • Javle MM, Smith PF, Prey JD, Clark KR, LeVea C, Nava HR, Schiff MD, Vinjamaram S, O'Malley L, Wilding GE, Nwogu CE, Yang G, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer investigation 2009; 272:193-200
  • Jing W, Gibson NW, Keane DM, Sun F-L, LeVea C, Brattain L, Sharatt EA, Dominiquez I, Beko A, Hauser J, Kuropatwinski K, Xiao-Qiong L, Rose R, Kan JLC, Rajput A, Brattain MG. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.Journal of biological chemistry 2009; 28416:10912-10922
  • Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas 2009; 105:523-527
  • Bir AS, Fora AA, Levea C, Fakih MG. Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer research 2009; 292:465-468
  • Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP : Journal of the pancreas 2009; 105:535-538
  • Ongchin M, Sharratt E, Dominguez I, Simms N, Wang J, Cheney R, LeVea C, Brattain M, Rajput A. The effects of epidermal growth factor receptor activation and attenuation of the TGFbeta pathway in an orthotopic model of colon cancer. Journal of surgical research 2009; 1562:250-256
  • Rajput A, Brattain MG, Hoffman RM, Mazurchuk R, Sharratt E, Levea C, Beko A, Rose R, Dominguez San Martin I, Wang J. Characterization of HCT116 human colon cancer cells in an orthotopic model. Journal of surgical research 2008; 1472:276-281
  • Fakih MG, Park YM, Puthillath A, Levea C, Ross ME, Rustum YM, Andrews C, Toth K, Pendyala L, Yang GY, Bullarddunn K, Rajput A. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. International journal of radiation oncology, biology, physics 2008; 723:650-657
  • Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.American journal of clinical oncology 2008; 314:329-334
  • Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG. Significance of signet-ring cells in patients with colorectal cancer. Diseases of the colon and rectum 2008; 511:50-55
  • Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. Journal of gastrointestinal surgery 2007; 114:445-451
  • Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Annals of surgical oncology 2007; 142:752-758
  • Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 2007; 735-6:281-289
  • Guo XN, Brattain MG, Hoffman RM, LeVea C, Kuropatwinski K, Beko A, Hauser J, Rose R, Rajput A, Wang J. Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.Cancer research 2007; 6712:5851-5858
  • Gupta B, LeVea C, Litwin A, Fakih MG. Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clinical colorectal cancer 2007; 66:447-449